Language
English
Publication Date
1-1-2024
Journal
PLoS One
DOI
10.1371/journal.pone.0289902
PMID
38683834
PMCID
PMC11057735
PubMedCentral® Posted Date
4-29-2024
PubMedCentral® Full Text Version
Post-print
Abstract
Mantle cell lymphoma (MCL) has a poor prognosis and high relapse rates despite current therapies, necessitating novel treatment regimens. Inhibition of SRC-3 show effectiveness in vivo and in vitro in other B cell lymphomas. Additionally, previous studies have shown that SRC-3 is highly expressed in the lymph nodes of B cell non-Hodgkin's lymphoma patients, suggesting SRC-3 may play a role in the progression of B cell lymphoma. This study aimed to investigate novel SRC-3 inhibitors, SI-10 and SI-12, in mantle cell lymphoma. The cytotoxic effects of SI-10 and SI-12 were evaluated in vitro and demonstrated dose-dependent cytotoxicity in a panel of MCL cell lines. The in vivo efficacy of SI-10 was confirmed in two ibrutinib-resistant models: an immunocompetent disseminated A20 mouse model of B-cell lymphoma and a human PDX model of MCL. Notably, SI-10 treatment also resulted in a significant extension of survival in vivo with low toxicity in both ibrutinib-resistant murine models. We have investigated SI-10 as a novel anti-lymphoma compound via the inhibition of SRC-3 activity. These findings indicate that targeting SRC-3 should be investigated in combination with current clinical therapeutics as a novel strategy to expand the therapeutic index and to improve lymphoma outcomes.
Keywords
Lymphoma, Mantle-Cell, Animals, Humans, Mice, Cell Line, Tumor, Adenine, Piperidines, Antineoplastic Agents, Pyrimidines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Pyrazoles, Female
Published Open-Access
yes
Recommended Citation
Bijou, Imani; Liu, Yang; Lu, Dong; et al., "Inhibition of Src-3 as a Potential Therapeutic Strategy for Aggressive Mantle Cell Lymphoma" (2024). Faculty and Staff Publications. 338.
https://digitalcommons.library.tmc.edu/baylor_docs/338
Included in
Biochemistry, Biophysics, and Structural Biology Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Biology Commons, Genetic Phenomena Commons, Hematology Commons, Hemic and Lymphatic Diseases Commons, Oncology Commons